SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


SPRINGWORKS THERAPEUTICS, INC. (SWTX)

Today's Latest Price: $85.29 USD

5.40 (6.76%)

Updated Jan 22 4:00pm

Add SWTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

SWTX Stock Price Chart Interactive Chart >

Price chart for SWTX

SWTX Price/Volume Stats

Current price $85.29 52-week high $87.60
Prev. close $79.89 52-week low $19.50
Day low $80.41 Volume 381,000
Day high $87.60 Avg. volume 387,979
50-day MA $70.72 Dividend yield N/A
200-day MA $49.89 Market Cap 4.16B

SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.


SWTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SWTX Latest Social Stream


Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SpringWorks Therapeutics Inc that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

H.C. Wainwright Stick to Their Buy Rating for Springworks Therapeutics Inc

H.C. Wainwright Stick to Their Buy Rating for Springworks Therapeutics Inc

Investing.com | December 28, 2020

Is SWTX A Good Stock To Buy Now?

At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In this […]

Yahoo | December 17, 2020

SpringWorks Therapeutics Announces Executive Leadership Promotions

STAMFORD, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Badreddin Edris, Ph.D., currently Chief Business Officer, has been promoted to Chief Operating Officer, and L. Mary Smith, Ph.D., currently Senior Vice President of Clinical Research and Development, has been promoted to Chief Development Officer. “Badreddin and Mary have demonstrated exceptional leadership and execution in their respective roles, which have been critical to the growth of SpringWorks, and it is my great pleasure to announce their promotions,” said Saqib Islam, Chief Executive Officer of SpringWorks. “They both embo...

Yahoo | December 15, 2020

SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will participate in a Fireside Chat at the 3rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Wednesday, December 2, 2020 at 12:35 p.m. ET. A video webcast will be available on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.About SpringWorks Therapeutics SpringWorks is a clinical-sta...

Yahoo | November 24, 2020

Barclays Stick to Their Buy Rating for Springworks Therapeutics Inc

Barclays Stick to Their Buy Rating for Springworks Therapeutics Inc

Investing.com | November 13, 2020

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo 14.28%
3-mo 42.10%
6-mo 125.28%
1-year 147.07%
3-year N/A
5-year N/A
YTD 17.61%
2020 88.41%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6551 seconds.